People with low-risk, high-grade B-cell lymphoma may need fewer cycles of chemotherapy
The FLYER study found that four cycles of R-CHOP was no less effective than six cycles in people with stage 1 or 2 high-grade B-cell lymphoma and no risk factors.
News
Research and clinical trials
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
Acalabrutinib shows promise in Waldenström’s macroglobulinaemia
Phase 2 trial finds that acalabrutinib is active and well tolerated in people with Waldenström’s macroglobulinaemia
Polatuzumab vedotin improves outcomes for people with relapsed or refractory DLBCL
Promising results published in the Journal of Clinical Oncology in November.
Take part in the Lymphoma Coalition 2020 Global Patient Survey
We want to hear from you! Please share your experiences in this new survey.
Encouraging results for pembrolizumab in children with relapsed or refractory Hodgkin lymphoma
Promising early results of the KEYNOTE-51 study published in the Lancet Oncology
136,000 people in the UK are living with chronic cancer
A recent study published by Macmillan Cancer Support has found that most people who have chronic cancer are not getting the support they need.
HORIZONS study completes recruitment
Over 3,000 people have entered the HORIZONS study into the impact of cancer diagnosis and treatment on everyday life, including 719 people with lymphoma.
Potential new ‘gene signature’ for chronic lymphocytic leukaemia
A new ‘gene signature’ might help predict who will respond well to traditional chemotherapy and who might need alternative treatment.
Potential new marker for outcomes in Hodgkin lymphoma
A protein called sIL-2R might help predict outcomes in people with classical Hodgkin lymphoma.
Outcome of Hodgkin lymphoma in pregnant women is similar to that in non-pregnant women
Women diagnosed with Hodgkin lymphoma during pregnancy can be successfully treated during pregnancy with no harm to the unborn child.